多靶点粪便FIT-DNA检测技术在结直肠癌患者、配偶及一级亲属筛查中的应用研究  

Application of multitarget stool FIT-DNA test for cancer screening in colorectal cancer patients and their spouses and first-degree relatives

作　　者：关旭 马晨曦 王炜 朱德祥 庄奥博 王若谷 陈创奇[5] 李佳英[6] 裴海平[7] 魏少忠[8] 许剑民 孙学军[2] 王锡山 Guan Xu;Ma Chenxi;Wang Wei;Zhu Dexiang;Zhuang Aobo;Wang Ruogu;Chen Chuangqi;Li Jiaying;Pei Haiping;Wei Shaozhong;Xu Jianmin;Sun Xuejun;Wang Xishan(Department of Colorectal Surgery,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China;Department of General Surgery,The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an 710061,China;Department of General Surgery,Affiliated Zhongshan Hospital of Fudan University,Shanghai 200032,China;Department of Gastrointestinal Surgery,The Third Affiliated Hospital of Shandong First Medical University(Affiliated Hospital of Shandong Medical College),Ji'nan 250031,China;Department of Colorectal Surgery,Gastrointestinal Surgery Center,The First Affiliated Hospital of Sun Yat-sen University,Guangzhou 510080,China;Department of Colorectal Cancer Surgery,The Second Affiliated Hospital of Harbin Medical University,Harbin 150001,China;Department of General Surgery,Xiangya Hospital of Central South University,Changsha 410008,China;Department of Gastrointestinal Surgery,Hubei Cancer Hospital,Wuhan 430079,China)

机构地区：[1]国家癌症中心/国家肿瘤临床医学研究中心/中国医学科学院北京协和医学院肿瘤医院结直肠外科,北京100021 [2]西安交通大学第一附属医院普通外科,710061 [3]复旦大学附属中山医院普外科,上海200032 [4]山东第一医科大学第三附属医院(山东省医科院附属医院)胃肠外科,济南250031 [5]中山大学附属第一医院胃肠外科中心结直肠外科,广州510080 [6]哈尔滨医科大学附属第二医院结直肠肿瘤外科,150001 [7]中南大学湘雅医院普外科,长沙410008 [8]湖北省肿瘤医院胃肠外科,武汉430079

出　　处：《中华结直肠疾病电子杂志》2021年第3期237-242,共6页Chinese Journal of Colorectal Diseases(Electronic Edition)

基　　金：北京市科技计划(No.D171100002617002,No.D171100002617004)。

摘　　要：目的初步探究多靶点粪便FIT-DNA检测技术对结直肠癌筛查的有效性,同时探索结直肠癌患者配偶及其一级亲属的结直肠癌及癌前病变发病风险。方法采用新型多靶点粪便FIT-DNA联合检测技术对于2017年4月至2019年3月全国八家医院的结直肠外科或普外科就诊的结直肠癌患者、患者配偶及一级亲属进行检测,并结合肠镜结果评价其检测性能。结果共211名受试者均完成多靶点粪便FIT-DNA联合检测及肠镜检查,其中135例为结直肠癌患者(64.0%),47例为患者配偶(22.3%),29例为患者一级亲属(13.7%)。其中,患者配偶的肠镜病变检出率为14.9%(7/47),患者一级亲属的肠镜病变检出率为24.1%(7/29),均未有癌变检出。多靶点粪便FIT-DNA联合检测技术检测结直肠癌的敏感性为89.6%(121/135),特异度为96.8%(60/62)。结论本研究初步肯定了多靶点粪便FIT-DNA联合检测技术在结直肠癌筛查中的检测性能,为进一步开展大样本前瞻性研究奠定了良好的基础。Objective To assess the clinical performance of Multitarget stool FIT-DNA test for colorectal cancer(CRC)screening,and investigate the risk factors of developing colorectal cancer and precancerous lesions in spouses and first-degree relatives of CRC patients.Methods CRC patients and their spouses and first-degree relatives were recruited from colorectal surgery or general surgery departments of eight hospitals in China between April 2017 to March 2019.Multitarget stool FIT-DNA test results were compared with colonoscopy outcomes.Results Of 211 valid participants,135(64.0%)were colorectal cancer patients,47(22.3%)were spouses and 29(13.7%)were first-degree relatives.Colonoscopy revealed14.9%(7/47)of spouses and 24.1%(7/29)of first-degree relatives had colonoscopic lesions.The sensitivity and specificity of Multitarget stool FIT-DNA test were 89.6%(121/135)and 96.8%(60/62)respectively.Conclusion The study confirmed the clinical performance of Multitarget stool FIT-DNA test in CRC screening,and provided essential data for large scale prospective study in the next stage.

关 键 词：结直肠肿瘤 多靶点粪便FIT-DNA检测技术 筛查 配偶 一级亲属 

分 类 号：R735.34[医药卫生—肿瘤]